Copyright © 2013-2018 Ascletis Pharma Inc. All rights reserved.
Home

News & Events

Investor

Careers

Pipeline

Partnership

About  Us

About Us

Our Science

OurScience Pipeline Partership Investor Careers
Contact
Contact    Home

Ravidavir

Ravidasvir

Ganovo

Ganovo

ASC06

ASC09

ASC06 ASC09

Overview

Pipeline

Our second HCV drug candidate, ravidasvir, which we believe  is  a best-in-class, NS5A protein inhibitor with pan-genotypic anti-viral activity, has completed a phase II/III clinical trial. We expect to file an NDA for ravidasvir in the third quarter of 2018. Our RDV/DNV Regimen (ravidasvir in combination with Ganovo and ribavirin) is an all-oral, interferon-free HCV therapy and demonstrates a 99% cure rate (SVR12) and a superior safety profile with a short treatment duration of 12 weeks. The current primary regimen in China has a cure rate of approximately 60% (SVR24) with a treatment duration of 48 to 72 weeks. Our RDV/DNV Regimen displays a higher genetic barrier to resistance than the approved regimens, Daklinza/Sunvepra. In patients with baseline NS5A resistance mutations, our phase II/III clinical trial showed that our RDV/DNV Regimen demonstrates a cure rate of 100% (SVR12).


Current Therapies and Limitations

See “Ganovo® Current Therapies and Limitations”


Advantages of Ravidasvir


We believe that, based on our clinical trials, our RDV/DNV Regimen has the potential to address the limitations of the current primary regimen for HCV in the following aspects:


• Best-in-class NS5A inhibitor. Our RDV/DNV Regimen demonstrated a 99% cure rate (SVR12) in the phase II/III clinical trial in China with 309 HCV genotype 1 patients. Our RDV/DNV Regimen was substantially more efficacious than the current primary regimen (48- to 72-week treatment duration) in China. The following diagram sets forth the virological response (RVR4, RVR8, EOT and SVR12) from this clinical trial.

• Highly efficacious for patients infected by HCV with baseline NS5A resistance mutations. The RDV/DNV Regimen demonstrated a 100% cure rate (SVR12) for patients with baseline NS5A resistance mutations in our phase II/III clinical trial. Six patients in our phase II clinical trial (EVEREST) had baseline NS5A resistance mutations and 100% of  these patients achieved SVR12. 19% of HCV patients in China carry baseline NS5A resistance mutations.   Competitor   products   demonstrated   a   cure   rate   of   20%   (SVR12)   in treating patients infected by HCV genotype 1b with baseline NS5A resistance mutations. The following diagrams set forth the SVR12 of patients with baseline NS5A resistance mutations in our phase II/III clinical trial and phase II clinical trial (EVEREST).

• Efficacious for hard-to-cure genotypes. Phase III clinical trial of RDV/SOF Regimen demonstrated a 99% cure rate (SVR12) in genotype 1a patients and 97% cure rate (SVR12) in genotype 3 patients. The following diagram sets forth the SVR12 of patients infected with hard-to-cure HCV genotypes in a phase III clinical trial for RDV/SOF Regimen.

• Efficacious in cirrhotic patients. Phase III clinical trial of RDV/SOF Regimen demonstrated a 96% cure rate (SVR12) in cirrhotic patients. The following diagram sets forth the SVR12 for cirrhotic patients in a phase III clinical trial.

• Efficacious for HCV/HIV co-infected patients. Phase III clinical trial of RDV/SOF Regimen demonstrated a 97% cure rate (SVR12) in HCV/HIV co-infected patients. The following diagram sets forth the SVR12 for HCV/HIV co-infected patients in a phase III clinical trial.

• Pan-genotypic anti-viral activity against genotypes 1 to 6. In vitro studies have shown that ravidasvir has potent anti-viral activity against HCV genotypes 1 to 6.  Two  phase  III clinical trials of RDV/SOF Regimen demonstrated an overall 97% cure rate (SVR12) in genotypes 1, 2, 3 and 6 and 95% cure rate (SVR12) in genotype 4. The following diagram sets forth the SVR12 for the HCV genotypes indicated below in phase III clinical trials.


• Shorter treatment duration. Our 12-week RDV/DNV Regimen is significantly shorter than the 48 to 72 week treatment duration of the current primary regimen. We believe that a shorter regimen will increase compliance to the treatment and improve patient tolerability.


• Superior safety and tolerability profile. Our phase II/III clinical trial have shown our RDV/DNV Regimen to be safe and well-tolerated. There were no treatment-related serious adverse events. Except for anemia and hyperuricemia, the occurrence of adverse event was similar between the RDV/DNV treatment group and placebo group. The higher occurrence rate of anemia in the RDV/DNV treatment group may be related to the use of ribavirin.

Source: DNDi, EASL The International Liver Congress April 2018

Source: DNDi, EASL The International Liver Congress April 2018

Source: DNDi, EASL The International Liver Congress April 2018; Cairo University, AASLD The Liver Meeting November 2015

Source: DNDi, EASL The International Liver Congress April 2018